Bio

Adam Walsh, MD, MBA, is a Managing Director and Senior Biotechnology Analyst at Roth Capital Partners. He is a veteran biotech equity research analyst with more than 20 years of experience covering innovative therapeutics across rare disease, immunology & inflammation, genetic medicine, and metabolic disease. He launched Jefferies' biotechnology equity research platform in 2002 as the firm's first analyst and later served as Managing Director and Senior Analyst at Canaccord Genuity and Stifel. At Stifel, he earned Thomson Reuters' #1 Overall Stock Picker and #2 Earnings Estimator awards in 2018. He has built his analyst reputation on rigorous, data-driven analysis and strong institutional investor relationships. His executive roles as Chief Financial Officer at jCyte and Catalytic Life Sciences gave him a first-hand operator's perspective, sharpening his ability to assess corporate strategy, financial discipline, and clinical execution. This blend of analyst rigor and executive insight provides him with a rare vantage point on the biotechnology sector from both investor and company perspectives.